---
title: "CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274513225.md"
description: "CSPC Pharmaceutical Group has received drug registration approval in mainland China for its fast-acting intravenous antihypertensive drug, Clevidipine Injectable Emulsion. This drug is designed for patients whose hypertension is not effectively managed with oral therapy, offering rapid blood pressure control without the need for dose adjustments. The approval enhances CSPC's cardiovascular product pipeline and addresses the demand for acute-care hypertension treatments in Chinese hospitals. Analysts rate the stock as a Buy with a price target of HK$10.50."
datetime: "2026-02-02T12:10:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274513225.md)
  - [en](https://longbridge.com/en/news/274513225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274513225.md)
---

# CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

The latest announcement is out from CSPC Pharmaceutical Group ( (HK:1093) ).

CSPC Pharmaceutical Group has secured drug registration approval in mainland China for its Clevidipine Injectable Emulsion, a fast-acting intravenous antihypertensive drug indicated for patients whose hypertension cannot be effectively managed with oral therapy. The formulation offers rapid, precise blood pressure control, does not require dose adjustments for patients with hepatic or renal dysfunction, and can be administered without dilution, addressing clinical needs in hypertensive emergencies. The new approval broadens CSPC’s cardiovascular product pipeline, strengthens its competitive position in this high-value therapeutic segment, and is expected to help meet unmet demand for acute-care hypertension treatments in Chinese hospitals.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

**More about CSPC Pharmaceutical Group**

CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company focused on developing, manufacturing and marketing a broad range of medicines, with an expanding portfolio in key therapeutic areas such as cardiovascular disease. Listed on the Hong Kong Stock Exchange, the group pursues innovation-driven growth in China’s healthcare market through the development of advanced formulations and hospital-use injectable products.

**YTD Price Performance:** 13.88%

**Average Trading Volume:** 120,526,022

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$110.4B

Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [562050.CN](https://longbridge.com/en/quote/562050.CN.md)

## Related News & Research

- [CSPC Wins U.S. and China Trial Approvals for New Oncology Antibody-Drug Conjugate](https://longbridge.com/en/news/284559073.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [AstraZeneca's blood pressure drug wins U.S. approval](https://longbridge.com/en/news/286720674.md)
- [Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus | OTLC Stock News](https://longbridge.com/en/news/286276734.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)